M&A Deal Summary |
|
|---|---|
| Date | 2021-09-13 |
| Target | TetraGenetics |
| Sector | Life Science |
| Buyer(s) | AbCellera Biologics |
| Deal Type | Add-on Acquisition |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 2012 |
| Sector | Life Science |
| Employees | 586 |
| Revenue | 29M USD (2024) |
AbCellera Biologics is a drug discovery platform that searches and analyzes natural immune systems to find antibodies that can be used to prevent and treat disease. AbCellera Biologics was founded in 2012 and is based in Vancouver, British Columbia.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 2 |
| Sector: Life Science M&A | 2 of 2 |
| Type: Add-on Acquisition M&A Deals | 1 of 1 |
| State: Massachusetts M&A | 1 of 1 |
| Country: United States M&A | 2 of 2 |
| Year: 2021 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-08-20 |
Dualogics - OrthoMab Bispecific Platform
Chapel Hill, North Carolina, United States Dualogics LLC - OrthoMab Bispecific Platform can combine any two existing antibody sequences to create bispecifics that are 99% identical to natural human antibodies. OrthoMab antibodies are produced using standard production and purification techniques and are available in flexible formats that can be tailored to specific target biology and mechanisms of action. |
Buy | - |
